# GLP-1 side effects, from first dose to long term

> GLP-1 side effects from the labels: how often nausea, hair loss and tiredness happen, when they ease, the serious warnings, and a simple way to track yours.

Canonical page: https://handlehealth.co/glp-1-side-effects · Category: Side effects · Last checked against sources: 2026-09-23

GLP-1 side effects are mostly digestive: nausea, diarrhea, vomiting and constipation, reported most often while the dose is being stepped up. This guide sets out what each medicine's label reports, the less talked-about effects such as hair loss and burping, the rare warnings that need a doctor quickly, and what trials found about muscle and about stopping. Every figure links to its source.

## In short

- The most common GLP-1 side effects are digestive: nausea, diarrhea, vomiting, constipation and stomach pain. In the Wegovy 2.4 mg weight-management trials, for example, 44% of people reported nausea, against 16% on placebo.[2]
- The Ozempic, Mounjaro and Zepbound labels say most reports of nausea, vomiting and diarrhea came during dose escalation, and the Mounjaro and Zepbound labels add that they decreased over time.[1][3][4]
- Less common effects include hair loss (3.3% on Wegovy 2.4 mg and 4–5% on Zepbound, against 1% on placebo, and linked to weight reduction), burping, tiredness and injection-site reactions.[2][4]
- Uncommon but serious warnings include pancreatitis, gallbladder disease, kidney injury from dehydration and serious allergic reactions, and the US labels carry a boxed warning about thyroid C-cell tumors, a finding from rodent studies whose relevance to people is unknown.[1][2][5]
- In trials where people switched from the medicine to placebo, much of the lost weight returned on average. That makes regain a signal to discuss with your prescriber, not a personal failure.[2][4]

## How common are GLP-1 side effects?

Stomach and bowel side effects lead every label. These are the rates on each medicine in its own US trials, with the placebo rate in brackets; ranges cover the doses studied. The trials differ, so the rows can't be ranked against each other.

| Medicine and trial population | Nausea | Vomiting | Diarrhea | Constipation |
|---|---|---|---|---|
| **Ozempic** 0.5–1 mg weekly injection: adults with type 2 diabetes[1] | 15.8–20.3% (6.1%) | 5–9.2% (2.3%) | 8.5–8.8% (1.9%) | 3.1–5% (1.5%) |
| **Wegovy** 2.4 mg weekly injection: adults with obesity or overweight[2] | 44% (16%) | 24% (6%) | 30% (16%) | 24% (11%) |
| **Mounjaro** 5–15 mg weekly injection: adults with type 2 diabetes[3] | 12–18% (4%) | 5–9% (2%) | 12–17% (9%) | 6–7% (1%) |
| **Zepbound** 5–15 mg weekly injection: adults with obesity or overweight[4] | 25–29% (8%) | 8–13% (2%) | 19–23% (8%) | 11–17% (5%) |
| **Foundayo** 5.5–17.2 mg daily tablet: adults with obesity or overweight[5] | 26–35% (10%) | 13–24% (4%) | 21–25% (11%) | 20–27% (9%) |

*Sources: each medicine's US prescribing information. Ozempic, two diabetes trials;[1] Wegovy, STEP 1–3, up to 68 weeks;[2] Mounjaro, SURPASS-1 and SURPASS-5;[3] Zepbound, SURMOUNT-1 and SURMOUNT-2, 72 weeks;[4] Foundayo, ATTAIN-1 and ATTAIN-2, 72 weeks.[5] The Wegovy pill's label says its common side effects were similar in type and frequency to the Wegovy injection's.[2]*

### Which GLP-1 has the fewest side effects?

The labels can't tell you, and they say so: side-effect rates from one medicine's trials "cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice."[1] The trials enrolled different people, used different doses and ran for different lengths of time.

Even one molecule shows why. Semaglutide's nausea rate was 15.8–20.3% in Ozempic's diabetes trials and 44% in Wegovy's weight-management trials, which used a higher dose in a different population.[1][2] Which medicine suits you depends on your health, your other medicines and your coverage, so it's a question for your prescriber. Our guide to [GLP-1 medications](https://handlehealth.co/glp-1-medications) sets out the differences, and [semaglutide vs tirzepatide](https://handlehealth.co/semaglutide-vs-tirzepatide) covers the head-to-head trials of the two.

## GLP-1 side effects by medicine

Each medicine has its own label, its own trials and its own questions. These guides take them one at a time.

- **[Mounjaro side effects](https://handlehealth.co/mounjaro-side-effects)** Tirzepatide for type 2 diabetes in the US, and for weight management too in the UK and EU. Also covers tirzepatide side effects.
- **[Zepbound side effects](https://handlehealth.co/zepbound-side-effects)** Tirzepatide for weight management and obstructive sleep apnea in the US, from its weight-management trials.
- **[Ozempic side effects](https://handlehealth.co/ozempic-side-effects)** Semaglutide injection for type 2 diabetes, the newer Ozempic tablets and the question of "Ozempic face". Also covers semaglutide side effects.
- **[Wegovy side effects](https://handlehealth.co/wegovy-side-effects)** Semaglutide for weight management: the weekly injection, the higher Wegovy HD dose and the daily Wegovy pill.
- **[Foundayo side effects](https://handlehealth.co/foundayo-side-effects)** Orforglipron, a once-daily tablet for weight management that can be taken with or without food.

## When GLP-1 side effects start and ease

The labels describe a pattern rather than a timetable. Your own weeks may look different.

- **Starting out — The dose starts low.** Labels begin with a low dose and step it up gradually, and they give the reason: to reduce the risk of stomach side effects. Your prescriber sets the steps.[1][2]
- **Each step up — Most reports come during escalation.** The Ozempic, Mounjaro and Zepbound labels say most reports of nausea, vomiting and diarrhea occurred during dose escalation. Wegovy's says they were most often reported then.[1][2][3][4]
- **The weeks after — They usually become less frequent.** The Mounjaro and Zepbound labels say these events decreased over time, and Foundayo's says the same of nausea, vomiting and diarrhea.[3][4][5]
- **The first months — Most people who stopped did so early.** In Zepbound's weight-management trials, most people who stopped because of side effects did so in the first few months of treatment, mainly because of stomach side effects.[4]
- **Whenever you lose fluids — Dehydration needs attention.** Vomiting and diarrhea can dehydrate you. The labels warn that this can lead to kidney injury, and ask prescribers to keep an eye on kidney function, especially when starting or stepping up.[1][2]

*A side effect that is severe, or that doesn't settle, is worth a call to your care team whenever it happens.*

## Nausea, diarrhea and constipation: what can help

General, non-drug measures. They don't replace your care team's advice, and none of them involves changing your medicine.

- Ask your care team whether smaller meals, eaten slowly, and going easy on greasy or fried food might help with nausea.
- Sip fluids through the day. The Wegovy Medication Guide says drinking fluids helps reduce your chance of dehydration.[2]
- For constipation, ask your care team whether more fluids and fiber-containing foods, such as fruit, vegetables and whole grains, would suit you.
- Check with your prescriber or pharmacist before taking any other medicine for side effects.

Contact your care team if you can't keep fluids down, if vomiting or diarrhea is severe or keeps going, if constipation is severe or comes with stomach pain, or if side effects stop you eating or drinking normally.

### Note how you feel in seconds, every day (in Handle)

Handle's daily check-in asks about nausea every day, plus the symptoms you switch on, such as diarrhea, constipation, vomiting or dizziness. It's the same short card whatever you answer.

Handle records what you report and never diagnoses. It is not a monitoring or emergency service, so if a symptom worries you, contact your care team, and if you feel very unwell, get medical help straight away.

- Takes seconds, including on the days you feel fine
- Track up to six more symptoms, such as belching, headache or fatigue, or one in your own words
- Missed a day? Add it later, up to 30 days back
- A private note for the day that nothing reads and no report includes

## Less talked-about GLP-1 side effects

Less common than stomach side effects, and easy to miss in a label. Placebo rates are in brackets.

- **Hair loss.** Reported by 3.3% on Wegovy 2.4 mg (1%), 4–5% on Zepbound (1%) and 4–5% on Foundayo (2%), and more often by women: 7.1% of women on Zepbound, against 0.5% of men.[2][4][5] The Wegovy and Zepbound labels say it was associated with weight reduction. For Ozempic and Mounjaro, alopecia appears only among reports made after approval, and no label describes hair loss as sudden or permanent.[1][3]
- **Burping.** The label term is eructation: 7% on Wegovy 2.4 mg (under 1%), 4–5% on Zepbound (1%) and 6–8% on Foundayo (1%).[2][4][5] "[Sulfur burps](https://handlehealth.co/sulfur-burps)" isn't a label term, and the labels say nothing about smell.
- **Tiredness, dizziness and headache.** Fatigue was reported by 11% on Wegovy 2.4 mg (5%), 5–7% on Zepbound (3%) and 6–9% on Foundayo (4%); dizziness by 8% on Wegovy (4%); headache by 14% on Wegovy (10%).[2][4][5] Wegovy's label notes that some episodes of low blood pressure were related to stomach side effects and fluid loss.[2]
- **Injection-site reactions.** Discomfort or redness where you inject: 6–8% on Zepbound (2%), 3.2% on Mounjaro (0.4%), 1.4% on Wegovy (1%) and 0.2% on Ozempic.[1][2][3][4] The labels ask you to rotate sites; see [Mounjaro injection sites](https://handlehealth.co/mounjaro-injection-sites) and [Ozempic and Wegovy injection sites](https://handlehealth.co/ozempic-injection-sites).
- **Changes in skin sensation.** Dysesthesia, meaning altered skin sensation such as burning or skin pain, was reported by 22% on the Wegovy 7.2 mg dose, against 6% on 2.4 mg and 0.3% on placebo.[2]

## Serious GLP-1 side effects and warnings

These are uncommon, but every label lists them. Figures are from the trials: on the medicine, then on placebo.

| Warning | What the labels say |
|---|---|
| **Pancreatitis** | Inflammation of the pancreas, including severe and fatal cases. Confirmed cases were uncommon in trials: 0.2 per 100 patient-years on Wegovy, against under 0.1 on placebo.[2] |
| **Gallbladder disease** | Gallstones in 1.6% on Wegovy, against 0.7%. Rapid weight loss can raise the risk, but Wegovy's label says the difference held even after accounting for the weight lost.[2] |
| **Kidney injury from dehydration** | Most reported cases followed nausea, vomiting or diarrhea that led to dehydration, and some needed dialysis.[1] |
| **Low blood sugar** | Mainly with insulin or a sulfonylurea: with a sulfonylurea, 17.3–24.4% on Ozempic had symptomatic low blood sugar confirmed by a glucose reading. Your prescriber may adjust your other diabetes medicines.[1] |
| **Serious allergic reactions** | Anaphylaxis and angioedema (swelling, for example of the face or throat) have been reported. A previous serious reaction to the medicine is a reason not to take it.[1] |
| **Severe stomach and bowel problems** | Severe stomach side effects in 4.1% on Wegovy, against 0.9%. Bowel blockage (ileus or obstruction) and severe constipation have been reported since approval. Not recommended with severe gastroparesis.[2] |
| **Eye complications in type 2 diabetes** | Diabetic retinopathy complications in 3.0% on Ozempic against 1.8% on placebo over two years, and more often in people who already had retinopathy.[1] |
| **Thyroid C-cell tumors (boxed warning)** | Seen in rodents; unknown whether they occur in people. Not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.[1][5] |

*Aspiration under anesthesia, the eye condition NAION and mood are covered below.*

> **Get medical help straight away if you have**
> - Severe stomach pain that won't go away, sometimes spreading to your back, with or without vomiting. The labels warn about pancreatitis.[1]
> - Signs of a serious allergic reaction, such as swelling of your face, lips, tongue or throat, or trouble breathing.[1]
> - Nausea, vomiting or diarrhea that won't go away, or that stops you keeping fluids down. The labels warn that dehydration can lead to kidney injury.[1]
> - A sudden loss of vision. EU and UK regulators list NAION as a very rare side effect of semaglutide.[7][8]
> - Thoughts of suicide or of harming yourself. In the US, call or text 988.[6]

> **Tell your care team soon about**
> - A lump or swelling in your neck, trouble swallowing, shortness of breath or hoarseness that won't go away. The labels ask prescribers to tell patients about these possible signs of a thyroid tumor.[1]
> - New or worsening low mood, or any unusual change in mood or behavior.[6]
> - Any planned surgery, procedure or sedation.[1]
> - Pregnancy plans, as early as you can. The semaglutide labels say to stop at least 2 months before a planned pregnancy.[1][2]

### Surgery and sedation

GLP-1 medicines slow the emptying of the stomach. Their US labels warn of rare reports of pulmonary aspiration, where stomach contents get into the lungs, in people having general anesthesia or deep sedation, even when they had followed fasting instructions.[1] The labels say the data are too limited to recommend changing fasting or stopping the medicine beforehand, and ask you to tell your healthcare providers you take it before any planned surgery or procedure.[1]

Beyond that, guidance differs by country. Guidance published in 2024 by five medical societies, including the American Society of Anesthesiologists, says the medicine may be continued in people without features that raise the risk, with precautions such as a 24-hour liquid diet when the risk is higher.[9] The UK regulator asks anesthetists to assess each person's risk and advises patients not to stop treatment without first discussing it with their doctor.[10] Your surgical or anesthesia team will tell you what applies to you.

### NAION, a very rare eye condition

NAION (non-arteritic anterior ischemic optic neuropathy) is a condition of the optic nerve that can cause sudden loss of vision. In June 2025 the European Medicines Agency concluded it is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking it, and the UK's medicines regulator reached a similar view in February 2026.[7][8]

Those reviews covered semaglutide medicines (Ozempic, Rybelsus and Wegovy), not other GLP-1s, and NAION isn't listed in any US label.[7][8] A sudden loss of vision needs urgent medical attention, whatever medicine you take.

### Mood, and a warning that was removed

Until February 2026, the US labels for Wegovy, Saxenda and Zepbound included a warning about suicidal thoughts and behavior.[2][4][6] In January 2026 the FDA asked for it to be removed, after an analysis of 91 placebo-controlled trials with 107,910 patients found no increased risk of suicidal thoughts or behavior, or of related problems such as anxiety or depression.[6]

The FDA still asks people to tell their health care professional about new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior. In the US, you can call or text 988.[6]

## Muscle and lean mass

When weight comes off, some of it is lean mass rather than fat. The semaglutide, tirzepatide and orforglipron labels each say the medicine lowers body weight with greater fat mass loss than lean mass loss.[2][4][5]

A 2025 analysis pooling 22 randomized trials of GLP-1 medicines found that lean mass made up about a quarter of the weight lost.[11] Lean mass isn't the same as muscle, though. It also includes organs, bone and body water, and a 2024 review notes that changes in lean mass may not reflect changes in muscle.[12]

If muscle is a concern, ask your care team whether a protein or activity target makes sense for you. Handle records protein and your resistance and cardio sessions separately, shows targets only if your clinician set them, and never estimates muscle. More in our [GLP-1 food tracker guide](https://handlehealth.co/glp-1-food-tracker).

## Long-term GLP-1 side effects

Most label tables come from trials lasting up to about 72 weeks.[2][4] Longer outcome trials add to the picture: in SELECT, which followed people taking Wegovy or placebo for a median of 41.8 months, 16% stopped the study medicine because of an adverse event, against 8% on placebo.[2]

Wegovy's label also reports more hip and pelvis fractures on semaglutide in that trial, in women (1% against 0.2%) and in people aged 75 and over (2.4% against 0.6%).[2] Other questions are still open: the thyroid warning rests on rodent studies whose relevance to people is unknown, and NAION was recognized as a very rare side effect of semaglutide only in 2025.[1][7]

## What happens after you stop a GLP-1

In trials where people switched from the medicine to placebo, weight tended to come back. In SURMOUNT-4, people who had lost an average of 20.9% on tirzepatide regained 14.0% of their body weight over the following 52 weeks on placebo, while those who continued lost a further 5.5%.[4] In STEP 4, people switched from semaglutide to placebo regained 6.9% over 48 weeks, while those who continued lost another 7.9%.[2]

Regain after stopping was the average experience in these trials, so it isn't a personal failure. It's a signal worth taking to your prescriber, and decisions about continuing, changing or stopping a medicine are ones to make together. Handle keeps the months before and after any change on one record.

### Show your prescriber the pattern, not just the worst day (Handle Premium)

A consultation report gathers your record for an appointment: your medication history including any switches, symptom summaries, weight history, nutrition and activity, and an optional note about what you want to discuss. It helps your clinician see the pattern quickly.

- Share a secure link and revoke it whenever you like
- Your private daily notes are never included
- Your clinician needs no account to read it

## Questions to ask your prescriber

A record is most useful when it feeds a conversation. For a simple way to keep one, see our [GLP-1 side effect tracker guide](https://handlehealth.co/glp-1-side-effect-tracker) and how to [prepare for a GLP-1 doctor appointment](https://handlehealth.co/glp-1-doctor-appointment).

1. Which side effects should I call you about, and which can I manage at home?
2. Do any of my other medicines, such as insulin, a sulfonylurea or the contraceptive pill, need a closer look?
3. I have a procedure coming up. Who should I tell, and what applies to me?
4. What would you like me to track between appointments?
5. If I stop this medicine one day, what's the plan afterwards?

## Questions people ask

### What are the most common side effects of GLP-1 medications?

Stomach and bowel side effects: nausea, diarrhea, vomiting, constipation and stomach pain. How often depends on the medicine, the dose and who was studied; in the Wegovy 2.4 mg weight-management trials, for example, 44% reported nausea against 16% on placebo.[2] The labels say most reports came while the dose was being stepped up, and some add that they decreased over time.[1][3][4]

### How long do GLP-1 side effects last?

The labels don't give a number of weeks. They say most reports of nausea, vomiting and diarrhea came during dose escalation, and the Mounjaro and Zepbound labels say these decreased over time.[1][3][4] If a side effect is severe, lasts, or stops you eating or drinking normally, contact your care team rather than waiting it out.

### Which GLP-1 has the least side effects?

The labels can't rank them. Each medicine's rates come from its own trials, and the labels say they cannot be directly compared with another drug's.[1] Even one medicine varies: semaglutide's nausea rate was 15.8–20.3% in Ozempic's diabetes trials and 44% in Wegovy's weight-management trials, at a higher dose in different people.[1][2] Your prescriber can weigh what matters for you.

### Do GLP-1 medications cause hair loss?

Hair loss is listed. It was reported by 3.3% on Wegovy 2.4 mg and 4–5% on Zepbound, against 1% on placebo, more often by women than men, and both labels say it was associated with weight reduction.[2][4] For Ozempic and Mounjaro it appears only in reports made after approval, and no label describes it as sudden or permanent.[1][3]

### Do GLP-1s make you tired?

Tiredness is a listed side effect. Fatigue was reported by 11% on Wegovy 2.4 mg against 5% on placebo, 5–7% on Zepbound against 3%, and 6–9% on Foundayo against 4%.[2][4][5] Tell your care team if it's new, severe or getting worse, and note it in your record so you can show when it started.

### Do GLP-1 medications cause muscle loss?

Some lean mass is lost along with fat. Across 22 randomized trials, lean mass made up about a quarter of the weight lost, and the labels say fat loss was greater than lean loss.[2][11] Lean mass isn't the same as muscle, since it also includes organs, bone and water.[12] Ask your care team whether a protein or activity target makes sense for you.

### What happens when you stop taking a GLP-1?

In trials, weight tended to return. People switched to placebo regained 14.0% of body weight over 52 weeks after tirzepatide in SURMOUNT-4, and 6.9% over 48 weeks after semaglutide in STEP 4, while those who continued kept losing.[2][4] Regain isn't a personal failure. Plan any change with your prescriber.

### Do GLP-1 pills have fewer side effects than injections?

The labels don't suggest so. Foundayo tablets had nausea rates of 26–35% against 10% on placebo in their weight trials, and the Wegovy pill's label says its common side effects were similar in type and frequency to the Wegovy injection's.[2][5] Pills and injections were tested in different trials, so exact rates can't be ranked. See [Wegovy side effects](https://handlehealth.co/wegovy-side-effects) and [Foundayo side effects](https://handlehealth.co/foundayo-side-effects).

### Do GLP-1 medications cause cancer?

The US labels carry a boxed warning about thyroid C-cell tumors, which occurred in rodents; whether they occur in people is unknown.[1] That's why these medicines are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Tell your care team about a neck lump, trouble swallowing, shortness of breath or hoarseness that won't go away.[1]

## Sources

1. Novo Nordisk, via DailyMed (U.S. National Library of Medicine). [Ozempic (semaglutide) injection — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79), effective June 1, 2026.
2. Novo Nordisk, via DailyMed (U.S. National Library of Medicine). [Wegovy (semaglutide) injection and Wegovy (semaglutide) tablets — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b), effective June 18, 2026.
3. Eli Lilly and Company, via DailyMed (U.S. National Library of Medicine). [Mounjaro (tirzepatide) injection — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0), effective August 27, 2026.
4. Eli Lilly and Company, via DailyMed (U.S. National Library of Medicine). [Zepbound (tirzepatide) injection — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b), effective August 28, 2026.
5. Eli Lilly and Company, via DailyMed (U.S. National Library of Medicine). [Foundayo (orforglipron) tablets — Prescribing Information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62), effective July 29, 2026.
6. U.S. Food and Drug Administration, Drug Safety Communication. [FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications](https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp), January 13, 2026.
7. European Medicines Agency. [PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy](https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy), June 6, 2025, revised June 13, 2025.
8. Medicines and Healthcare products Regulatory Agency (UK), Drug Safety Update. [Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)](https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion), February 5, 2026.
9. Kindel TL et al., Surgical Endoscopy (AGA, ASMBS, ASA, ISPCOP and SAGES), via PubMed Central. [Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period](https://pmc.ncbi.nlm.nih.gov/articles/PMC11666732/), published online October 2024.
10. Medicines and Healthcare products Regulatory Agency (UK), Drug Safety Update. [GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation](https://www.gov.uk/drug-safety-update/glp-1-and-dual-gip-slash-glp-1-receptor-agonists-potential-risk-of-pulmonary-aspiration-during-general-anaesthesia-or-deep-sedation), January 28, 2025.
11. Karakasis P et al., Metabolism, via PubMed. [Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/39719170/), 2025.
12. Neeland IJ et al., Diabetes, Obesity and Metabolism, via PubMed. [Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies](https://pubmed.ncbi.nlm.nih.gov/38937282/), 2024.

## About Handle

Handle is a GLP-1 treatment companion. It keeps your dose record, a short daily check-in, weight, food, drinks and activity in one calm place, and turns them into a summary you can choose to share with your clinician.

Handle supports recording and conversations with your care team. It does not diagnose, and it never tells you to start, change, skip or stop a dose. This page is general information, not medical advice. Always follow your prescriber and your medicine's instructions for use.